MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) signed a binding letter of intent (LOI) to acquire SKNY Pharmaceuticals, Inc. The ...

Mira Pharmaceuticals is making moves in weight loss and smoking cessation. The biotech is trying to buy Skny Pharmaceuticals ...

MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...

MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical ...

If approved by the FDA, MIRA-55 could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders. The U.S. Drug Enforcement ...

s (NASDAQ:MIRA) Phase 1 trial for Ketamir-2, the company's novel oral ketamine analog in development for neuropathic pain. In December, MIRA Pharmaceuticals submitted an Investigational New Drug (IND) ...